Is Riboxil/Calilon a targeted drug?

Ribociclib is an oral small molecule inhibitor classified as a CDK4/6 inhibitor. This type of drug is widely considered to be a typical targeted therapy drug. The original purpose of its research and development is to inhibit the progression of tumors by precisely acting on the key signaling pathways of cancer cells. Unlike traditional chemotherapy drugs that directly kill rapidly dividing cells, Riboxiclib inhibits cancer cell proliferation by specifically inhibiting cyclin-dependent kinase 4 and 6 (CDK4/6), blocking tumor cells from entering the S phase from the G1 phase. This precise mechanism of action at the molecular level is a typical feature of targeted drugs.

In clinical application, Riboxiclib is usually used in combination with endocrine therapy drugs, especially for female patients with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Multiple international clinical studies have shown that reboxiclib combined with aromatase inhibitors or fulvestrant can significantly extend the progression-free survival of patients and improve the overall efficacy. This combined treatment model has gradually become the first-line treatment recommended by international guidelines. Because of this, Riboxiclib quickly attracted widespread attention from oncologists and patients after it was launched in China.

From the perspective of drug classification, Riboxiclib is not only a targeted drug, but is also included in the emerging field of "cell cycle inhibitors". In recent years, with the deepening of the concept of molecular targeted therapy, CDK4/6 inhibitors have gradually become an important pillar in the treatment of breast cancer. Compared with traditional chemotherapy, targeted drugs tend to have higher therapeutic selectivity and better tolerance. Although there are certain side effects, the overall risk is controllable and can be reduced through monitoring and dose adjustment. Common side effects of Riboxil include neutropenia, increased liver function indicators and fatigue, but most patients can successfully complete the treatment under the guidance of a doctor.

Reference materials:https://us.kisqali.com/